Juvenile myasthenia gravis with prepubertal onset
- PMID: 10093062
- DOI: 10.1016/s0960-8966(98)00077-7
Juvenile myasthenia gravis with prepubertal onset
Abstract
Juvenile myasthenia gravis (JMG) with prepubertal onset is an uncommon disease. We studied 19 patients with age at onset ranging from 1.5 to 9.2 years and compared their clinical characteristics and response to therapy with 114 cases with MG onset after the prepubertal age, up to 20 years. Neither sex prevalence nor autoimmune diseases other than MG were found in younger patients. Although ocular myasthenia was more frequent than in later-onset JMG, children with generalized symptoms were often severely affected and respiratory involvement was present in 8/19 patients. Anti-acetylcholine receptor antibodies were detected at a lower rate and, in contrast with results in older patients, seronegativity was more frequent among children with generalized disease. Three out of six patients with onset before the age of five showed spontaneous remission. Nine prepubertal patients underwent thymectomy and, as most of them also received immunosuppressive therapy, the influence of surgery on disease outcome remains unclear; in no case was thymoma found. This is in contrast to the good results after thymectomy and the presence of thymoma in the later-onset group. Eleven patients in the prepubertal series were treated with immunosuppressive therapy. At the end of follow-up, most patients were in good condition. The frequency of immunosuppressive therapy and the rate of good therapeutic results did not differ from those observed in older patients.
Similar articles
-
Acetylcholine receptor antibodies in juvenile myasthenia gravis.Neurology. 1993 May;43(5):977-82. doi: 10.1212/wnl.43.5.977. Neurology. 1993. PMID: 8492956
-
Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort.Eur J Paediatr Neurol. 2017 Sep;21(5):707-714. doi: 10.1016/j.ejpn.2017.04.003. Epub 2017 Apr 20. Eur J Paediatr Neurol. 2017. PMID: 28457757
-
Myasthenia gravis in children: a longitudinal study.Acta Neurol Scand. 2006 Aug;114(2):119-23. doi: 10.1111/j.1600-0404.2006.00646.x. Acta Neurol Scand. 2006. PMID: 16867035
-
Pediatric Myasthenia Gravis.Semin Pediatr Neurol. 2017 May;24(2):116-121. doi: 10.1016/j.spen.2017.04.003. Epub 2017 Apr 7. Semin Pediatr Neurol. 2017. PMID: 28941526 Review.
-
[Therapeutic strategy in myasthenia gravis].Rev Neurol (Paris). 2009 Feb;165(2):149-54. doi: 10.1016/j.neurol.2009.01.005. Rev Neurol (Paris). 2009. PMID: 19233080 Review. French.
Cited by
-
Juvenile myasthenia gravis: a paediatric perspective.Autoimmune Dis. 2011;2011:404101. doi: 10.4061/2011/404101. Epub 2011 Nov 1. Autoimmune Dis. 2011. PMID: 22110902 Free PMC article.
-
The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review.Front Neurol. 2022 Feb 23;13:834212. doi: 10.3389/fneur.2022.834212. eCollection 2022. Front Neurol. 2022. PMID: 35280301 Free PMC article. Review.
-
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress.BioDrugs. 2025 May;39(3):373-409. doi: 10.1007/s40259-025-00708-2. Epub 2025 Mar 29. BioDrugs. 2025. PMID: 40156757 Free PMC article. Review.
-
Autoimmune neuromuscular disorders in childhood.Curr Treat Options Neurol. 2011 Dec;13(6):590-607. doi: 10.1007/s11940-011-0146-5. Curr Treat Options Neurol. 2011. PMID: 21912840 Free PMC article.
-
Juvenile myasthenia: diagnosis and treatment.Paediatr Drugs. 2000 May-Jun;2(3):161-9. doi: 10.2165/00128072-200002030-00001. Paediatr Drugs. 2000. PMID: 10937467 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical